StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

StockNews.com began coverage on shares of Senseonics (NYSE:SENS - Free Report) in a research report released on Saturday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reissued a "buy" rating and set a $2.00 price objective on shares of Senseonics in a research note on Friday.

Senseonics Price Performance

Senseonics stock remained flat at $0.28 during trading hours on Friday. The company's stock had a trading volume of 6,141,279 shares, compared to its average volume of 2,886,795. Senseonics has a 12 month low of $0.28 and a 12 month high of $0.75. The company has a market cap of $167.77 million, a PE ratio of -2.17 and a beta of 0.79. The firm has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.40. The company has a quick ratio of 2.89, a current ratio of 2.47 and a debt-to-equity ratio of 59.17.

Institutional Investors Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its position in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company's stock worth $59,000 after acquiring an additional 167,970 shares during the last quarter. State Board of Administration of Florida Retirement System purchased a new stake in shares of Senseonics in the first quarter valued at $91,000. GSA Capital Partners LLP acquired a new position in Senseonics in the third quarter valued at $117,000. Virtu Financial LLC purchased a new position in Senseonics during the first quarter worth about $162,000. Finally, Symmetry Partners LLC acquired a new stake in Senseonics in the 3rd quarter worth about $164,000. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.